ClinicalTrials.gg
CompletedNCT03281863Updated Mar 26, 2021

Clinical Audit on the Managment in Assiut University Children Hospital

An observational study in Rheumatic Fever, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2021-03-26.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
5 Years to 15 Years
Sex
All
01

Study summary

clinical audit on the Managment of rheumatic fever in assiut university children hospital.

Read the detailed description

Acute rheumatic fever,an auto immune response to Group A streptococcus infection of the upper respiratory tract,may result in carditis.when the inflammation leads to permenant damage of the valves the individual has rheumatic heart disease.

Recurrences of rheumatic fever are likely in the absence of preventive measures and may cause further cardiac valve and muscle damage,leading to heart failure,stroke and premature death.bacterial endocarditis is also a complication.

02

Conditions studied

  • Rheumatic Fever

Browse trials for

03

In context

Rheumatic Fever

55 studies on the registry are indexed under Rheumatic Fever; 21 are open to participants now.

This study's enrollment of 100 is below the median of 300 across 26 observational studies indexed under Rheumatic Fever.

Browse Rheumatic Fever studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Clinical audit on the managment of rheumatic fever in assiut university children hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with confirmed diagnosis of rheumatic fever based on laboratory investigations.

Exclusion criteria

Exclusion Criteria:

  • No
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testC reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate

    Throat culture to detect the causative organism

    Also known as: Throat culture

06

What researchers measure

Primary outcomes

  1. laboratory investigations (ASOt , ESR . CRP)

    laboratory investigations that measure the inflammation process will be used and the target that the ASOt not increase 1/400

    Time frame: One year from October 2017 to september 2018

Secondary outcomes

  1. clinical measures

    improvement of arthritis if found

    Time frame: One year from October 2017 to september 2018

07

Study locations

1 site
  • Egypt
    Assiut, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Mar 2020, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2017
First posted
Sep 13, 2017
StartActual
Oct 1, 2018
Primary completionActual
Mar 24, 2020
CompletionActual
Mar 24, 2020
Last update
Mar 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03281863
Lead sponsor
Assiut University
Responsible party
Patricia reda hanna (Resident doctor, Assiut University) — Principal investigator
First posted
Sep 13, 2017
Start date
Oct 1, 2018
Primary completion
Mar 24, 2020
Completion
Mar 24, 2020
Last update
Mar 26, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion